Artificial intelligence in drug discovery: A comprehensive review with a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy

Ao Shang; Cheng Xin; Cheng Zhang; Guang Chen; Guoyi Tang; Junwei Su; Ning Wang; Ruogu Xiong; Shan Wu; Xiaoyu Xu

REVIEW 3 major objections 6 minor 300 references

Artificial intelligence in drug discovery: A comprehensive review with a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy

T0 review · 3 major / 6 minor · reviewed 2026-08-06 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read AI/ML boosts drug discovery efficiency, accuracy, and cost-effectiveness.

desk verdict A useful but overstated review: the gout case study largely documents network pharmacology, not AI/ML, and the epidemiology numbers need correcting. read the letter →

arxiv 2507.03407 v1 pith:PGCZ22F6 submitted 2025-07-04 cs.AI q-bio.QM

Junwei Su , Cheng Xin , Ao Shang , Shan Wu , Zhenzhen Xie , Ruogu Xiong , Xiaoyu Xu , Cheng Zhang

show 6 more authors

Guang Chen Yau-Tuen Chan Guoyi Tang Ning Wang Yong Xu Yibin Feng

This is my paper · ORCID

classification cs.AIq-bio.QM

keywords artificialintelligencemachinelearningdrugdiscoverytargetidentificationvirtualscreeningleadoptimizationhyperuricemiagout

verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This review argues that artificial intelligence and machine learning have become central tools across the entire drug discovery pipeline, from target identification through hit screening and lead optimization to clinical trial design. It assembles evidence that ML-driven methods extract targets from biomedical literature, networks, and omics data; navigate vast chemical spaces through virtual screening, QSAR, and generative models; and predict pharmacokinetics, toxicity, and trial outcomes. A case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy grounds these claims, showing network pharmacology and ML-guided screening nominating targets such as xanthine oxidase, URAT1, ABCG2, and NLRP3, and identifying small-molecule and peptide xanthine-oxidase inhibitors, several experimentally validated. The conclusion asserts that AI/ML has significantly enhanced the efficiency, accuracy, and cost-effectiveness of drug discovery, while acknowledging persistent obstacles in data quality, model interpretability, and experimental validation. A sympathetic reader would take the paper as a structured orientation to a field whose tools are already affecting practice.

What carries the argument

The object carrying the argument is the staged drug-discovery pipeline itself, treated as three interdependent phases: target identification, hit screening, and lead optimization. The methodological machinery differs by phase: transformer-based NLP for mining biomedical text, graph neural networks for network-medicine target discovery, deep learning over omics data, ML-enhanced scoring functions and QSAR models for virtual screening, and variational autoencoders, GANs, diffusion models, and reinforcement learning for de novo molecule design, with tree-based and hybrid Bayesian-ML models for pharmacokinetic and toxicity prediction. Inside the case study, the recurring mechanism is network pharmacology, a workflow that constructs drug-compound-target networks and combines them with molecular docking, molecular dynamics simulations, and experimental validation to nominate targets and hits for hyperuricemia, gout, and hyperuricemic nephropathy.

What would settle it

Count, across Tables 2–4 of the case study, how many studies actually train a machine-learning model (e.g., a supervised QSAR model, a deep network, or a graph neural network) versus how many use only network pharmacology, docking, or molecular dynamics; if the ML-trained count is a small minority, the paper's central example of AI/ML-driven success in hyperuricemia and gout loses its evidentiary weight.

Watch

Extended reading notes

Core claim

The central claim, stated in the conclusion, is that AI/ML methodologies have significantly enhanced the efficiency, accuracy, and cost-effectiveness of drug discovery, and that a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy underscores both the substantial successes and the ongoing challenges of AI/ML integration. The review supports this claim by threading the argument through three interdependent stages: target identification, where NLP, network medicine, and omics analysis reveal disease-relevant proteins; hit screening and generation, where ML-empowered virtual screening, QSAR, and generative models explore chemical space; and lead optimization, where ML predicts pharmacokinetic, toxicity, and clinical outcomes. The case-study section compiles dozens of studies that used network pharmacology, molecular docking, and some ML-QSAR modeling to nominate targets and hit compounds, and it highlights ML-driven transcriptional profiling as a target-agnostic route to candidate drugs. The paper also states that no AI/ML-driven lead-optimization approach is dedicated to these diseases, a gap that limits the case study's reach relative to the full pipeline it describes.

Load-bearing premise

The case study counts many network pharmacology and molecular docking studies as AI/ML applications, but most of those studies use no machine learning at all, so the abstract's claim of 'real-world successes' for AI/ML depends on a classification that may not hold.

Editorial extensions

If this is right

If the review is right, AI/ML becomes the default first-pass filter in target identification, with literature and network-based methods prioritizing targets before experimental validation.
ML-scored virtual screening and generative models will keep expanding the chemical space explored per research dollar, making ultra-large-library screening a routine starting point.
Earlier and more accurate ML prediction of pharmacokinetics and toxicity should shift lead optimization to computational triage, lowering the cost of late-stage clinical failures.
For hyperuricemia and gout specifically, the compiled target lists (XOD, URAT1, ABCG2, NLRP3 pathway, and apoptosis regulators) provide concrete, testable candidates for drug repurposing and new inhibitor design.
The paper's admitted absence of AI/ML lead-optimization campaigns for these diseases implies that the next natural step is applying existing lead-optimization methods to the hits already identified.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

This reviewer's inference: the case-study successes are not a clean measure of AI/ML impact, because the urate field's targets are mostly well-characterized enzymes and transporters that favor docking and QSAR over harder learning problems.
A testable extension would be to feed the compiled XOD-inhibitor hits into modern generative models with property optimization, since the review finds no dedicated ML lead-optimization for these diseases.
The review's stage-dependence framing suggests the largest near-term gains may lie at stage interfaces, such as feeding predicted targets directly into generative hit design, rather than strengthening any single stage in isolation.
Given the cited projection of roughly 958 million gout cases by 2050, even a small increase in urate-lowering therapy success rates would carry large population-level benefits, which raises the practical stakes for validating the computational targets the review catalogs.

Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Desk Editor's Note

read the letter

Jason,

This is a solid orientation review rather than a research contribution. The authors cover the AI/ML drug discovery pipeline in three sections (target identification, hit screening, lead optimization) and then present a disease-specific case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy. The case-study tables (Tables 2–4) compile around 70 network-pharmacology and docking studies and are genuinely useful for a TCM-oriented audience; the figures are clear. They also review the few actual ML hit-discovery efforts in that disease space (QSAR for XOD inhibitors, DLEPS for perillen) and honestly admit in Section 5.4 that no sufficient AI/ML-driven lead optimization exists for these diseases. That admission is a point in their favor.

The soft spots. The abstract promises 'real-world successes in molecular target identification and therapeutic candidate discovery' attributable to AI/ML. But the case-study tables classify entries by methods, and nearly all use network pharmacology and molecular docking, which are deterministic computational biology, not machine learning. The paper says at the start of Section 5.2 that AI/ML techniques 'along with conventional approaches' are involved, yet the tables do not separate the two, so a reader cannot tell which targets were actually found by ML. This overstates the evidence. The stress-test note is on target. The epidemiology numbers in Section 5.1 also appear off by an order of magnitude: the paper reports 558 million gout prevalent cases in 2020, while the GBD 2021 paper they cite gives about 55.8 million, and the 95% CI of '811–116' for 2050 looks like a typo. Those numbers need checking. Finally, no systematic search method is reported, so the selection of case-study papers may be biased toward the authors' own prior work and TCM journals.

None of this is fatal for a review, but the abstract's 'real-world successes' claim needs qualification and the numbers need correction.

Who benefits? Researchers in TCM and gout who want a quick map of the field. I would not cite it for a substantive claim, but I would point students to it. Send it to peer review—the topic matters and the tables are valuable—but ask for major revision to fix the AI/ML attribution and the epidemiology errors.

Referee Report

3 major / 6 minor

Summary. This review surveys AI/ML techniques applied across the drug discovery pipeline—target identification, hit screening, and lead optimization—and then presents a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy. The central claim, stated in the conclusion, is that AI/ML methodologies have significantly enhanced the efficiency, accuracy, and cost-effectiveness of drug discovery, with the case study invoked as evidence of real-world successes in molecular target identification and therapeutic candidate discovery.

Significance. If the claims are properly scoped, the review offers a useful broad orientation to a rapidly evolving field, particularly for readers seeking a pipeline-level overview. The paper is strongest when describing concrete computational methods in Sections 2–4, such as ML-based QSAR, deep learning for toxicity prediction, and generative models. The disease-specific case study is a potentially valuable addition because hyperuricemia and related conditions have unmet therapeutic needs and limited prior AI/ML-focused reviews. However, the evidentiary weight of the case study depends on classifying network pharmacology and molecular docking as AI/ML, a categorization that the manuscript itself does not justify. Once that classification is corrected or the claims are narrowed, the review would be a credible orientation resource.

major comments (3)

[5.2, Tables 2–4] The case-study tables use coded methods—network pharmacology (①), molecular docking (②), molecular dynamics, metabolomics, transcriptomics, and wet-lab assays—with no code for machine learning or deep learning. Section 5.2 introduces these studies as involving 'AI/ML techniques, along with conventional approaches,' but the text never distinguishes which table entries actually employ AI/ML. Because the abstract attributes 'real-world successes in molecular target identification and therapeutic candidate discovery' to AI/ML, and because the majority of Table 2–4 entries are deterministic network-pharmacology and docking pipelines, the causal link between AI/ML and these successes is not established. Please reclassify each study's AI/ML content or restrict the success claims to the explicit ML-based studies in Section 5.3.
[5.4 and Abstract/Conclusion] Section 5.4 concedes that 'there are no sufficient AI/ML-driven approaches specifically designed for lead optimization' for hyperuricemia, gout arthritis, and hyperuricemic nephropathy. Yet the conclusion asserts that AI/ML has 'significantly enhanced the efficiency, accuracy, and cost-effectiveness of drug discovery' across the whole pipeline. The case study therefore cannot support a pipeline-wide claim; it covers target identification and hit screening only, with a gap at lead optimization. Please align the abstract and conclusion with the actual scope of the case study, presenting it as an early-stage illustration rather than evidence for the full drug discovery pipeline.
[Abstract and Sections 5.2–5.3] The abstract's phrase 'real-world successes' overstates the evidence: most identified targets and hits are computational predictions with in vitro or in vivo validation, and Section 5.2 itself notes that 'further translational and clinical studies involving humans are warranted.' No clinical-stage candidate from these AI/ML-assisted studies is described. Suggest replacing 'real-world successes' with language such as 'computational and preclinical findings' to accurately represent the level of validation shown in the case study.

minor comments (6)

[Figure 2 caption] The caption reads 'AL/ML-aided novel network pharmacology'; 'AL' should be 'AI'.
[4.2] The text states that recent studies address 'the four following fields' but then enumerates five items: biologics and protein-based drug modeling, small-molecule PK parameter prediction, personalized PK modeling, ADME and toxicology models, and hybrid modeling. Please correct the count or merge the categories.
[5.1] The sentence 'with an increase rate of lager than 70%' contains a typo; 'lager' should be 'larger'.
[Abbreviations] In the abbreviation list, 'V AE' appears with a space; use 'VAE' for consistency with the rest of the text.
[4.4] Section 4.4, titled 'Clinical trial optimization', includes a discussion of protein language models for target discovery and protein design; this material fits better in Section 2 or 3. Consider moving it or retitling the subsection to reflect the broader AI/ML-in-trial-development content.
[5.2 (general)] The review claims systematic coverage, but the selection criteria for the studies in Tables 2–4 are not described. A brief statement of the search strategy, inclusion criteria, and screening process would strengthen reproducibility.

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity: the paper is a literature review with no fitted parameters, no derivation-from-own-inputs, and no load-bearing self-citation chain.

full rationale

This manuscript is a narrative review of AI/ML in drug discovery followed by a disease-specific literature survey. There is no mathematical derivation, no model fitting, and no prediction generated from the paper's own equations or parameters. The case study in Section 5 compiles externally published network pharmacology, molecular docking, and ML-QSAR studies (Tables 2–4); these are presented as literature findings, not as outputs of a model constructed in this paper. The paper explicitly concedes in Section 5.4 that there are 'no sufficient AI/ML-driven approaches specifically designed for lead optimization' for hyperuricemia and related diseases, which is a stated limitation rather than a circular justification. The only arguable weakness is the classification of network pharmacology and molecular docking as AI/ML techniques in the case study, but this is a categorization or evidential-weight concern, not circular reasoning: the review does not define network pharmacology in terms of the conclusions it draws, nor does it fit a parameter to a dataset and then predict that same dataset. No self-citations are load-bearing; the cited prior work appears to be independent published studies. The central conclusion that AI/ML has 'significantly enhanced the efficiency, accuracy, and cost-effectiveness of drug discovery' is a summary of external literature and is therefore supported or challenged by the quality of that literature, not by a circular derivation.

Assumptions & free parameters 0 free parameters · 2 assumptions · 0 invented entities

The central claim is a review claim, not a derivation. No free parameters or invented entities are introduced. Two domain assumptions are load-bearing: the assumed effectiveness of AI/ML in drug discovery, and the categorization of network pharmacology studies under the AI/ML umbrella for the case study.

assumptions (2)

domain assumption AI/ML can significantly enhance drug discovery efficiency, accuracy, and cost-effectiveness.
This is the central premise of the review, stated in the introduction and conclusion, and it is not independently demonstrated by the paper.
ad hoc to paper Network pharmacology can be grouped under the AI/ML umbrella for the purpose of the case study.
The case study labels network pharmacology studies as AI/ML applications, but network pharmacology is traditionally a systems biology approach that may not involve machine learning. This classification is load-bearing for the claim that the case study demonstrates AI/ML success.

how reviews work

0 comments

Cite this review

Pith. "Pith review of Artificial intelligence in drug discovery: A comprehensive review with a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy." pith.science (2026). https://pith.science/paper/PGCZ22F6

@misc{pith2026250703407,
  author       = {Pith},
  title        = {Pith review of: Artificial intelligence in drug discovery: A comprehensive review with a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/PGCZ22F6}},
  note         = {Machine review of arXiv:2507.03407}
}

read the original abstract

This paper systematically reviews recent advances in artificial intelligence (AI), with a particular focus on machine learning (ML), across the entire drug discovery pipeline. Due to the inherent complexity, escalating costs, prolonged timelines, and high failure rates of traditional drug discovery methods, there is a critical need to comprehensively understand how AI/ML can be effectively integrated throughout the full process. Currently available literature reviews often narrowly focus on specific phases or methodologies, neglecting the dependence between key stages such as target identification, hit screening, and lead optimization. To bridge this gap, our review provides a detailed and holistic analysis of AI/ML applications across these core phases, highlighting significant methodological advances and their impacts at each stage. We further illustrate the practical impact of these techniques through an in-depth case study focused on hyperuricemia, gout arthritis, and hyperuricemic nephropathy, highlighting real-world successes in molecular target identification and therapeutic candidate discovery. Additionally, we discuss significant challenges facing AI/ML in drug discovery and outline promising future research directions. Ultimately, this review serves as an essential orientation for researchers aiming to leverage AI/ML to overcome existing bottlenecks and accelerate drug discovery.

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

300 extracted references · 80 canonical work pages

[1]

Nature Reviews Drug Discovery, 2023

Mullowney, M.W., et al., Artificial intelligence for natural product drug discovery. Nature Reviews Drug Discovery, 2023. 22(11): p. 895-916

2023
[2]

Molecular Therapy Nucleic Acids, 2023

Chen, W., et al., Artificial intelligence for drug discovery: Resources, methods, and applications. Molecular Therapy Nucleic Acids, 2023. 31: p. 691-702

2023
[3]

Gangwal, A. and A. Lavecchia, Unleashing the power of generative AI in drug discovery. Drug Discovery Today, 2024. 29(6): p. 24

2024
[4]

Briefings in Bioinformatics, 2024

McGibbon, M., et al., From intuition to AI: evolution of small molecule representations in drug discovery. Briefings in Bioinformatics, 2024. 25(1): p. 13

2024
[5]

Pharmaceuticals, 2023

Blanco-González, A., et al., The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals, 2023. 16(6): p. 11

2023
[6]

Expert Opinion on Drug Discovery, 2024

Pinheiro, P.D.M., et al., Molecular hybridization: a powerful tool for multitarget drug discovery. Expert Opinion on Drug Discovery, 2024. 19(4): p. 451-470

2024
[7]

European Journal of Pharmaceutical Sciences, 2023

Vemula, D., et al., CADD, AI and ML in drug discovery: A comprehensive review. European Journal of Pharmaceutical Sciences, 2023. 181: p. 23

2023
[8]

Artificial Intelligence Review, 2023

Askr, H., et al., Deep learning in drug discovery: an integrative review and future challenges. Artificial Intelligence Review, 2023. 56(7): p. 5975-6037

2023

Show all 300 references

[9]

Jama Psychiatry, 2024

Winter, N.R., et al., A Systematic Evaluation of Machine Learning -Based Biomarkers for Major Depressive Disorder. Jama Psychiatry, 2024. 81(4): p. 386 - 395

2024
[10]

Pharmaceutics, 2023

V ora, L.K., et al., Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 2023. 15(7): p. 46

2023
[11]

Hasselgren, C. and T.I. Oprea, Artificial Intelligence for Drug Discovery: AreWe There Yet? Annual Review of Pharmacology and Toxicology, 2024. 64: p. 527-550

2024
[12]

Computational and Structural Biotechnology Journal, 2021

Carracedo-Reboredo, P., et al., A review on machine learning approaches and trends in drug discovery. Computational and Structural Biotechnology Journal, 2021. 19: p. 4538-4558

2021
[13]

International Journal of Molecular Sciences, 2023

Sarkar, C., et al., Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. International Journal of Molecular Sciences, 2023. 24(3): p. 40

2023
[14]

Zhang, W.J. and R.S. Huang, Computer -aided drug discovery strategies for novel therapeutics for prostate cancer leveraging next-generating sequencing data. Expert 36 Opinion on Drug Discovery, 2024. 19(7): p. 841-853

2024
[15]

Medicinal Research Reviews, 2021

Vatansever, S., et al., Artificial intelligence and machine learning -aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Medicinal Research Reviews, 2021. 41(3): p. 1427-1473

2021
[16]

Artificial Intelligence Review, 2022

Dara, S., et al., Machine Learning in Drug Discovery: A Review. Artificial Intelligence Review, 2022. 55(3): p. 1947-1999

2022
[17]

Sadybekov, A.V . and V . Katritch, Computational approaches streamlining drug discovery. Nature, 2023. 616(7958): p. 673-685

2023
[18]

Nature Reviews Drug Discovery, 2024

Tropsha, A., et al., Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nature Reviews Drug Discovery, 2024. 23(2): p. 141- 155

2024
[19]

20(2): p

Chandrasekaran, S.N., et al., Image -based profiling for drug discovery: due for a machine-learning upgrade? Nature Reviews Drug Discovery, 2021. 20(2): p. 145 - 159

2021
[20]

Insel, Editor

Zhu, H., Big Data and Artificial Intelligence Modeling for Drug Discovery, in Annual Review of Pharmacology and Toxicology, Vol 60, P.A. Insel, Editor. 2020, Annual Reviews: Palo Alto. p. 573-589

2020
[21]

Bender, A. and I. Cortés -Ciriano, Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discovery Today, 2021. 26(2): p. 511-524

2021
[22]

Grisoni, and G

Jiménez-Luna, J., F. Grisoni, and G. Schneider, Drug discovery with explainable artificial intelligence. Nature Machine Intelligence, 2020. 2(10): p. 573-584

2020
[23]

Expert Opinion on Drug Discovery, 2021

Jiménez-Luna, J., et al., Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opinion on Drug Discovery, 2021. 16(9): p. 949-959

2021
[24]

Pharmaceuticals, 2023

Han, R., et al., Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. Pharmaceuticals, 2023. 16(9): p. 34

2023
[25]

Visan, A.I. and I. Negut, Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life-Basel, 2024. 14(2): p. 36

2024
[26]

Scientific Reports, 2025

Xie, S.W., et al., A comprehensive analysis of trends in the burden of gout in China and globally from 1990 to 2021. Scientific Reports, 2025. 15(1): p. 14

1990
[27]

Scientific Reports, 2024

Punjwani, S., et al., Burden of gout among different WHO regions, 1990 -2019: estimates from the global burden of disease study. Scientific Reports, 2024. 14(1): p. 12

1990
[28]

Frontiers in Medicine, 2025

Li, M.Y ., et al., Assessing cross-national inequalities and predictive trends in gout burden: a global perspective (1990-2021). Frontiers in Medicine, 2025. 12: p. 19

1990
[29]

European Journal of Clinical Investigation, 37

Jeong, Y .J., et al., Global burden of gout in 1990-2019: A systematic analysis of the Global Burden of Disease study 2019. European Journal of Clinical Investigation, 37

1990
[30]

Nature chemical biology, 2013

Schenone, M., et al., Target identification and mechanism of action in chemical biology and drug discovery. Nature chemical biology, 2013. 9(4): p. 232--240

2013
[31]

Moll, J. and R. Colombo, Target identification and validation in drug discovery. 2019

2019
[32]

Nature reviews Drug discovery, 2021

Emmerich, C.H., et al., Improving target assessment in biomedical research: the GOT-IT recommendations. Nature reviews Drug discovery, 2021. 20(1): p. 64--81

2021
[33]

Vidanagamachchi, S.M. and K. Waidyarathna, Opportunities, challenges and future perspectives of using bioinformatics and artificial intelligence techniques on tropical disease identification using omics data. Frontiers in Digital Health, 2024. 6: p. 1471200

2024
[34]

Data Science and Management, 2025

Surur, F.M., et al., Unlocking the power of machine learning in big data: a scoping survey. Data Science and Management, 2025

2025
[35]

Briefings in Bioinformatics, 2021

Zhao, S., et al., Recent advances in biomedical literature mining. Briefings in Bioinformatics, 2021. 22(3): p. bbaa057

2021
[36]

Kumar, V .D. and H.J. Tipney, Biomedical literature mining. 2014

2014
[37]

Database, 2016

Hayman, G.T., et al., The Disease Portals, disease --gene annotation and the RGD disease ontology at the Rat Genome Database. Database, 2016. 2016: p. baw034

2016
[38]

Nucleic acids research, 2024

Zhou, Y ., et al., TTD: therapeutic target database describing target druggability information. Nucleic acids research, 2024. 52(D1): p. D1465--D1477

2024
[39]

arXiv preprint arXiv:2501.16255, 2025

Wang, Z., et al., A foundation model for human-AI collaboration in medical literature mining. arXiv preprint arXiv:2501.16255, 2025

2025 arXiv
[40]

European Journal of Technology, 2023

Bharadiya, J., A comprehensive survey of deep learning techniques natural language processing. European Journal of Technology, 2023. 7(1): p. 58--66

2023
[41]

BMC bioinformatics, 2022

Aldahdooh, J., et al., Using BERT to identify drug -target interactions from whole PubMed. BMC bioinformatics, 2022. 23(1): p. 245

2022
[42]

Nature communications,

Fernndez-Torras, A., et al., Integrating and formatting biomedical data as pre - calculated knowledge graph embeddings in the Bioteque. Nature communications,
[43]

PeerJ, 2024

Metzger, V .T., et al., TIN-X version 3: update with expanded dataset and modernized architecture for enhanced illumination of understudied targets. PeerJ, 2024. 12: p. e17470

2024
[44]

Frontiers in Artificial Intelligence, 2025

Liu, D., et al., SciLinker: a large -scale text mining framework for mapping associations among biological entities. Frontiers in Artificial Intelligence, 2025. 8: p. 1528562

2025
[45]

Frontiers in pharmacology, 2021

Smith, D.P., et al., Expert -augmented computational drug repurposing identified baricitinib as a treatment for COVID -19. Frontiers in pharmacology, 2021. 12: p. 709856. 38

2021
[46]

Scientific reports, 2020

Paliwal, S., et al., Preclinical validation of therapeutic targets predicted by tensor factorization on heterogeneous graphs. Scientific reports, 2020. 10(1): p. 18250

2020
[47]

Nature Biotechnology, 2025

Ren, F., et al., A small -molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology, 2025. 43(1): p. 63--75

2025
[48]

Zitnik, M., et al., Current and future directions in network biology, in Bioinformatics advances. 2024. p. vbae099

2024
[49]

Gene \& Protein in Disease, 2022

Wang, P., Network biology: Recent advances and challenges. Gene \& Protein in Disease, 2022. 1(2): p. 101

2022
[50]

Suratanee, and K

Janyasupab, P., A. Suratanee, and K. Plaimas, Network diffusion with centrality measures to identify disease-related genes. Math. Biosci. Eng, 2021. 18(3)

2021
[51]

Ghosh, and V

Rintala, T.J., A. Ghosh, and V . Fortino, Network approaches for modeling the effect of drugs and diseases. Briefings in Bioinformatics, 2022. 23(4): p. bbac229

2022
[52]

Gulbahce, and J

Barabsi, A.-L., N. Gulbahce, and J. Loscalzo, Network medicine: a network -based approach to human disease. Nature reviews genetics, 2011. 12(1): p. 56--68

2011
[53]

Chan, S.Y . and J. Loscalzo, The emerging paradigm of network medicine in the study of human disease. Circulation research, 2012. 111(3): p. 359--374

2012
[54]

IEEE Access, 2024

Paul, S.G., et al., A systematic review of graph neural network in healthcare -based applications: Recent advances, trends, and future directions. IEEE Access, 2024. 12: p. 15145--15170

2024
[55]

Bioinformatics, 2019

Zeng, X., et al., deepDR: a network -based deep learning approach to in silico drug repositioning. Bioinformatics, 2019. 35(24): p. 5191--5198

2019
[56]

Briefings in bioinformatics, 2021

Bagherian, M., et al., Machine learning approaches and databases for prediction of drug--target interaction: a survey paper. Briefings in bioinformatics, 2021. 22(1): p. 247--269

2021
[57]

Chemical Science, 2020

Zeng, X., et al., Target identification among known drugs by deep learning from heterogeneous networks. Chemical Science, 2020. 11(7): p. 1775--1797

2020
[58]

Thafar, and M

Alshahrani, M., M.A. Thafar, and M. Essack, Application and evaluation of knowledge graph embeddings in biomedical data. PeerJ Computer Science, 2021. 7: p. e341

2021
[59]

International Journal of Quantum Chemistry, 2023

Yang, B., et al., Open-circuit voltage loss and dielectric constants as new descriptors in machine learning study on organic photovoltaics. International Journal of Quantum Chemistry, 2023. 123(5): p. e27039

2023
[60]

Nature Machine Intelligence, 2021

Schulte-Sasse, R., et al., Integration of multiomics data with graph convolutional networks to identify new cancer genes and their associated molecular mechanisms. Nature Machine Intelligence, 2021. 3(6): p. 513--526

2021
[61]

Nature communications, 2024

Chen, H., et al., Drug target prediction through deep learning functional representation of gene signatures. Nature communications, 2024. 15(1): p. 1853. 39

2024
[62]

Malik, P., et al., Integration of AlphaFold Data in Drug Design and Discovery: A Promising Approach for Targeted Therapeutics. 2023. Volume 11,: p. 2455-6211

2023
[63]

Nature reviews Drug discovery, 2003

Bleicher, K.H., et al., Hit and lead generation: beyond high -throughput screening. Nature reviews Drug discovery, 2003. 2(5): p. 369--378

2003
[64]

Combinatorial chemistry \& high throughput screening, 2003

Alanine, A., et al., Lead generation -enhancing the success of drug discovery by investing in the hit to lead process. Combinatorial chemistry \& high throughput screening, 2003. 6(1): p. 51--66

2003
[65]

Onwuli, and A

Park, H., A. Onwuli, and A. Walsh, Exploration of crystal chemical space using text- guided generative artificial intelligence. Nature Communications, 2025. 16(1): p. 1- -14

2025
[66]

npj Drug Discovery, 2025

Iqbal, S., et al., Evaluation of DNA encoded library and machine learning model combinations for hit discovery. npj Drug Discovery, 2025. 2(1): p. 5

2025
[67]

Trends in Chemistry, 2021

Coley, C.W., Defining and exploring chemical spaces. Trends in Chemistry, 2021. 3(2): p. 133--145

2021
[68]

Current opinion in chemical biology, 2007

McInnes, C., Virtual screening strategies in drug discovery. Current opinion in chemical biology, 2007. 11(5): p. 494--502

2007
[69]

Journal of chemical information and modeling, 2012

Scior, T., et al., Recognizing pitfalls in virtual screening: a critical review. Journal of chemical information and modeling, 2012. 52(4): p. 867--881

2012
[70]

Journal of medicinal chemistry, 2010

Ripphausen, P., et al., Quo vadis, virtual screening? A comprehensive survey of prospective applications. Journal of medicinal chemistry, 2010. 53(24): p. 8461 -- 8467

2010
[71]

European Journal of Medicinal Chemistry, 2024: p

Dai, J., et al., Combined usage of ligand-and structure-based virtual screening in the artificial intelligence era. European Journal of Medicinal Chemistry, 2024: p. 117162

2024
[72]

Nature Communications, 2025

Carvajal-Patio, J.G., et al., RNAmigos2: accelerated structure -based RNA virtual screening with deep graph learning. Nature Communications, 2025. 16(1): p. 1--12

2025
[73]

Nature Communications, 2024

Zhou, G., et al., An artificial intelligence accelerated virtual screening platform for drug discovery. Nature Communications, 2024. 15(1): p. 7761

2024
[74]

Signal Transduction and Targeted Therapy, 2023

Yang, Z., et al., AlphaFold2 and its applications in the fields of biology and medicine. Signal Transduction and Targeted Therapy, 2023. 8(1): p. 115

2023
[75]

Beni -Suef University Journal of Basic and Applied Sciences, 2024

Uzoeto, H.O., et al., AlphaFold -latest: revolutionizing protein structure prediction for comprehensive biomolecular insights and therapeutic advancements. Beni -Suef University Journal of Basic and Applied Sciences, 2024. 13(1): p. 46

2024
[76]

Alhumaid, N.K. and E.A. Tawfik, Reliability of AlphaFold2 Models in Virtual Drug Screening: A Focus on Selected Class A GPCRs. International Journal of Molecular Sciences, 2024. 25(18): p. 10139

2024
[77]

Wei, H. and J.A. McCammon, Structure and dynamics in drug discovery. npj Drug Discovery, 2024. 1(1): p. 1. 40

2024
[78]

Briefings in Bioinformatics, 2022

Zheng, L., et al., Improving protein --ligand docking and screening accuracies by incorporating a scoring function correction term. Briefings in Bioinformatics, 2022. 23(3): p. bbac051

2022
[79]

Huang, S. -Y . and X. Zou, Advances and challenges in protein -ligand docking. International journal of molecular sciences, 2010. 11(8): p. 3016--3034

2010
[80]

BMC bioinformatics, 2025

Shirali, A., et al., A comprehensive survey of scoring functions for protein docking models. BMC bioinformatics, 2025. 26(1): p. 25

2025
[81]

Communications Chemistry,

Valsson, s., et al., Narrowing the gap between machine learning scoring functions and free energy perturbation using augmented data. Communications Chemistry,
[82]

Morris, and P.C

Meli, R., G.M. Morris, and P.C. Biggin, Scoring functions for protein-ligand binding affinity prediction using structure -based deep learning: a review. Frontiers in bioinformatics, 2022. 2: p. 885983

2022
[83]

Junaid, and W

Wang, B., M. Junaid, and W. Li, Graph convolutional neural networks improved target-specific scoring functions for cGAS and kRAS in virtual screening. Computational and Structural Biotechnology Journal, 2025

2025
[84]

Sivula, and A

Phner, I., T. Sivula, and A. Poso, Ultra-Large-Scale Virtual Screening, in Computer- Aided and Machine Learning -Driven Drug Design: From Theory to Applications
[85]

Nam, and S

Kim, J., J. Nam, and S. Ryu, Understanding active learning of molecular docking and its applications. 2024

2024
[86]

Nature Protocols, 2022

Gentile, F., et al., Artificial intelligence --enabled virtual screening of ultra -large chemical libraries with deep docking. Nature Protocols, 2022. 17(3): p. 672--697

2022
[87]

Nature Computational Science, 2024

Schneuing, A., et al., Structure-based drug design with equivariant diffusion models. Nature Computational Science, 2024. 4(12): p. 899--909

2024
[88]

arXiv preprint arXiv:2503.20913, 2025

Hu, X., et al., TransDiffSBDD: Causality-Aware Multi-Modal Structure-Based Drug Design. arXiv preprint arXiv:2503.20913, 2025

2025 arXiv
[89]

Biomarker Research, 2025

Ocana, A., et al., Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomarker Research, 2025. 13(1): p. 45

2025
[90]

Virtual screening: principles, challenges, and practical guidelines, 2011: p

Koeppen, H., et al., Ligand -Based Virtual Screening. Virtual screening: principles, challenges, and practical guidelines, 2011: p. 61--85

2011
[91]

Nisius, and J

Ripphausen, P., B. Nisius, and J. Bajorath, State -of-the-art in ligand -based virtual screening. Drug discovery today, 2011. 16(9-10): p. 372--376

2011
[92]

Scientific Reports, 2024

Cielak, M., et al., Machine learning accelerates pharmacophore -based virtual screening of MAO inhibitors. Scientific Reports, 2024. 14(1): p. 8228

2024
[93]

ACS omega, 2023

Karki, R., et al., Pharmacophore -based machine learning model to predict ligand selectivity for E3 ligase binders. ACS omega, 2023. 8(33): p. 30177--30185. 41

2023
[94]

Amendola, G. and S. Cosconati, PyRMD: a new fully automated AI-powered ligand- based virtual screening tool. Journal of Chemical Information and Modeling, 2021. 61(8): p. 3835--3845

2021
[95]

Science of The Total Environment, 2024

Wu, X., et al., A machine learning-based QSAR model reveals important molecular features for understanding the potential inhibition mechanism of ionic liquids to acetylcholinesterase. Science of The Total Environment, 2024. 915: p. 169974

2024
[96]

ACS omega, 2024

Fuadah, Y .N., et al., QSAR Classification Modeling Using Machine Learning with a Consensus-Based Approach for Multivariate Chemical Hazard End Points. ACS omega, 2024. 9(51): p. 50796--50808

2024
[97]

Journal of Chemical Information and Modeling, 2025

Liu, Y ., et al., Advancements in Ligand -Based Virtual Screening through the Synergistic Integration of Graph Neural Networks and Expert -Crafted Descriptors. Journal of Chemical Information and Modeling, 2025

2025
[98]

Vasilev, B. and M.A. Atanasova, Review of the Application of Quantitative Structure--Activity Relationship (QSAR) in the Prediction of New Compounds with Anti-Breast Cancer Activity. Appl. Sci, 2025. 15: p. 1206

2025
[99]

Soares, T.A., et al., The (Re) -Evolution of Quantitative Structure --Activity Relationship (QSAR) studies propelled by the surge of machine learning methods, in Journal of Chemical Information and Modeling. 2022. p. 5317--5320

2022
[100]

Journal of Chemical Information and Modeling,

Mervin, L., et al., QSARtuna: an automated qsar modeling platform for molecular property prediction in drug design. Journal of Chemical Information and Modeling,
[101]

Journal of chemical information and modeling, 2019

Yang, K., et al., Analyzing learned molecular representations for property prediction. Journal of chemical information and modeling, 2019. 59(8): p. 3370--3388

2019
[102]

Kumar, and J.C

Wang, C., G.A. Kumar, and J.C. Rajapakse, Drug discovery and mechanism prediction with explainable graph neural networks. Scientific Reports, 2025. 15(1): p. 179

2025
[103]

Nature Communications, 2023

Li, H., et al., A knowledge-guided pre-training framework for improving molecular representation learning. Nature Communications, 2023. 14(1): p. 7568

2023
[104]

Scientific reports, 2020

Tsou, L.K., et al., Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery. Scientific reports, 2020. 10(1): p. 16771

2020
[105]

ACS omega, 2024

Santos, E.S.d.A., et al., Deep Multitask Learning -Driven Discovery of New Compounds Targeting Leishmania infantum. ACS omega, 2024. 9(52): p. 51271 -- 51284

2024
[106]

Journal of Cheminformatics, 2019

Sadawi, N., et al., Multi-task learning with a natural metric for quantitative structure activity relationship learning. Journal of Cheminformatics, 2019. 11(1): p. 1--13

2019
[107]

Moon, C. and D. Kim, Prediction of drug --target interactions through multi -task 42 learning. Scientific Reports, 2022. 12(1): p. 18323

2022
[108]

BMC chemistry, 2024

Pitakbut, T., et al., Utilizing machine learning -based QSAR model to overcome standalone consensus docking limitation in beta -lactamase inhibitors screening: a proof-of-concept study. BMC chemistry, 2024. 18(1): p. 249

2024
[109]

Ahmadi, and A

Askarzade, A., S. Ahmadi, and A. Almasirad, SMILES-based QSAR and molecular docking studies of chalcone analogues as potential anti -colon cancer. Scientific Reports, 2025. 15(1): p. 6573

2025
[110]

Scientific Reports, 2024

Moussaoui, M., et al., QSAR, ADMET, molecular docking, and dynamics studies of 1, 2, 4-triazine-3 (2H)-one derivatives as tubulin inhibitors for breast cancer therapy. Scientific Reports, 2024. 14(1): p. 16418

2024
[111]

Wiley Interdisciplinary Reviews: Computational Molecular Science, 2022

Bai, Q., et al., Application advances of deep learning methods for de novo drug design and molecular dynamics simulation. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2022. 12(3): p. e1581

2022
[112]

Moretti, and J

Tang, Y ., R. Moretti, and J. Meiler, Recent advances in automated structure-based de novo drug design. Journal of Chemical Information and Modeling, 2024. 64(6): p. 1794--1805

2024
[113]

Chemical Reviews, 2025

Fesik, S.W., Drugging Challenging Cancer Targets Using Fragment-Based Methods. Chemical Reviews, 2025. 125(6): p. 3586--3594

2025
[114]

Sathya, and M.S

Devi, R.V ., S.S. Sathya, and M.S. Coumar, Evolutionary algorithms for de novo drug design--A survey. Applied Soft Computing, 2015. 27: p. 543--552

2015
[115]

Communications Chemistry, 2023

Ochiai, T., et al., Variational autoencoder -based chemical latent space for large molecular structures with 3D complexity. Communications Chemistry, 2023. 6(1): p. 249

2023
[116]

Nguyen, T. and A. Karolak, Transformer Graph Variational Autoencoder for Generative Molecular Design. Biophysical Journal, 2025

2025
[117]

Journal of chemical information and modeling, 2023

Pravalphruekul, N., et al., De novo design of molecules with multiaction potential from differential gene expression using variational autoencoder. Journal of chemical information and modeling, 2023. 63(13): p. 3999--4011

2023
[118]

Stanley, and D

Blanchard, A.E., C. Stanley, and D. Bhowmik, Using GANs with adaptive training data to search for new molecules. Journal of cheminformatics, 2021. 13: p. 1--8

2021
[119]

Ribeiro Vaz, and T

Macedo, B., I. Ribeiro Vaz, and T. Taveira Gomes, MedGAN: optimized generative adversarial network with graph convolutional networks for novel molecule design. Scientific reports, 2024. 14(1): p. 1212

2024
[120]

Journal of cheminformatics, 2022

Abbasi, M., et al., Designing optimized drug candidates with generative adversarial network. Journal of cheminformatics, 2022. 14(1): p. 40. 121.Lin, H., et al., Diffbp: Generative diffusion of 3d molecules for target protein binding. Chemical Science, 2025. 16(3): p. 1417--1431. 43

2022
[122]

Poczos, and N

Alakhdar, A., B. Poczos, and N. Washburn, Diffusion models in de novo drug design. Journal of Chemical Information and Modeling, 2024. 64(19): p. 7238--7256

2024
[123]

Computers in Biology and Medicine, 2024

Choi, S., et al., PIDiff: Physics informed diffusion model for protein pocket-specific 3D molecular generation. Computers in Biology and Medicine, 2024. 180: p. 108865

2024
[124]

Isayev, and A

Popova, M., O. Isayev, and A. Tropsha, Deep reinforcement learning for de novo drug design. Science advances, 2018. 4(7): p. eaap7885

2018
[125]

Journal of Chemical Information and Modeling, 2024

Bou, A., et al., ACEGEN: Reinforcement learning of generative chemical agents for drug discovery. Journal of Chemical Information and Modeling, 2024. 64(15): p. 5900--5911

2024
[126]

Jeon, W. and D. Kim, Autonomous molecule generation using reinforcement learning and docking to develop potential novel inhibitors. Scientific reports, 2020. 10(1): p. 22104

2020
[127]

Journal of Chemical Information and Modeling, 2015

Su, B.H., et al., Rule -based prediction models of cytochrome P450 inhibition. Journal of Chemical Information and Modeling, 2015. 55(7): p. 1426-1434

2015
[128]

Liu, P. and W. Long, Current mathematical methods used in QSAR/QSPR studies. International Journal of Molecular Sciences, 2009. 10(5): p. 1978-1998

2009
[129]

ACS omega, 2023

Einarson, K.A., et al., Molecular representations in machine -learning-based prediction of pk parameters for insulin analogs. ACS omega, 2023. 8(26): p. 23566- 23578

2023
[130]

Molecular pharmaceutics, 2022

Obrezanova, O., et al., Prediction of in vivo pharmacokinetic parameters and time – exposure curves in rats using machine learning from the chemical structure. Molecular pharmaceutics, 2022. 19(5): p. 1488-1504

2022
[131]

Scientific Reports, 2025

Patidar, K., et al., Development of an mPBPK machine learning framework for early target pharmacology assessment of biotherapeutics. Scientific Reports, 2025. 15

2025
[132]

ACS omega, 2022

Kwapien, K., et al., Implications of additivity and nonadditivity for machine learning and deep learning models in drug design. ACS omega, 2022. 7(30): p. 26573-26581

2022
[133]

Biological and Pharmaceutical Bulletin, 2022

Kamiya, Y ., et al., Machine learning prediction of the three main input parameters of a simplified physiologically based pharmacokinetic model subsequently used to generate time-dependent plasma concentration data in humans after oral doses of 212 dis parate chemicals. Biolog...

2022
[134]

Journal of Pharmaceutical Sciences, 2021

Iwata, H., et al., Prediction of total drug clearance in humans using animal data: proposal of a multimodal learning method based on deep learning. Journal of Pharmaceutical Sciences, 2021. 110(4): p. 1834-1841

2021
[135]

Journal of Chemical Information and Modeling, 2022

Iwata, H., et al., Predicting total drug clearance and volumes of distribution using the machine learning -mediated multimodal method through the imputation of various nonclinical data. Journal of Chemical Information and Modeling, 2022. 44 62(17): p. 4057-4065

2022
[136]

Pharmaceutical research,

Destere, A., et al., A hybrid algorithm combining population pharmacokinetic and machine learning for isavuconazole exposure prediction. Pharmaceutical research,
[137]

Clinical pharmacokinetics, 2021

Tang, B.H., et al., Drug clearance in neonates: a combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction. Clinical pharmacokinetics, 2021. 60: p. 1435-1448

2021
[138]

Pharmaceutics, 2022

Keutzer, L., et al., Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin. Pharmaceutics, 2022. 14(8): p. 1530

2022
[139]

Bies, and A

Khusial, R., R.R. Bies, and A. Akil, Deep learning methods applied to drug concentration prediction of olanzapine. Pharmaceutics, 2023. 15(4): p. 1139

2023
[140]

European Journal of Clinical Pharmacology, 2023

Ponthier, L., et al., Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation. European Journal of Clinical Pharmacology, 2023. 79(2): p. 311-319

2023
[141]

Hughes, J.H. and R.J. Keizer, A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT: pharmacometrics & systems pharmacology, 2021. 10(10): p. 1150-1160

2021
[142]

CPT: Pharmacometrics & Systems Pharmacology, 2022

Labriffe, M., et al., Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles. CPT: Pharmacometrics & Systems Pharmacology, 2022. 11(8): p. 1018-1028

2022
[143]

Molecules, 2023

Li, X., et al., Prediction of ADMET properties of anti-breast cancer compounds using three machine learning algorithms. Molecules, 2023. 28(5): p. 2326

2023
[144]

Frontiers in Genetics, 2023

An, T., et al., A machine learning -based approach to ER α bioactivity and drug ADMET prediction. Frontiers in Genetics, 2023. 13: p. 1087273

2023
[145]

Machine Learning: Science and Technology, 2020

Brereton, A.E., et al., Predicting drug properties with parameter -free machine learning: pareto-optimal embedded modeling (POEM). Machine Learning: Science and Technology, 2020. 1(2): p. 025008

2020
[146]

yunnanensis for Treating Rheumatoid Arthritis—An Assessment Combining Machine Learning–Guided ADME Properties Prediction, Network Pharmacology, and Pharmacological Assessment

Wang, X., et al., Gaultheria leucocarpa var. yunnanensis for Treating Rheumatoid Arthritis—An Assessment Combining Machine Learning–Guided ADME Properties Prediction, Network Pharmacology, and Pharmacological Assessment. Frontiers in Pharmacology, 2021. 12: p. 704040

2021
[147]

Applied Sciences, 2022

Karalis, V .D., Machine learning in Bioequivalence: towards identifying an appropriate measure of absorption rate. Applied Sciences, 2022. 13(1): p. 418

2022
[148]

Physical Chemistry Chemical Physics, 2023

Yang, L., et al., Transformer -based deep learning method for optimizing ADMET properties of lead compounds. Physical Chemistry Chemical Physics, 2023. 25(3): 45 p. 2377-2385

2023
[149]

Química Nova, 2023

Cobre, A.D.F., et al., Machine learning-based virtual screening, molecular docking, drug-likeness, pharmacokinetics and toxicity analyses to identify new natural inhibitors of the glycoprotein spike (S1) of SARS -CoV-2. Química Nova, 2023. 46(5): p. 450-459

2023
[150]

Clinical Pharmacokinetics, 2022

Destere, A., et al., A hybrid model associating population pharmacokinetics with machine learning: a case study with iohexol clearance estimation. Clinical Pharmacokinetics, 2022. 61(8): p. 1157-1165

2022
[151]

Molecules, 2022

Norinder, U., Traditional machine and deep learning for predicting toxicity endpoints. Molecules, 2022. 28(1): p. 217

2022
[152]

Advanced Science, 2025: p

Bai, C., et al., Machine Learning‐Enabled Drug‐Induced Toxicity Prediction. Advanced Science, 2025: p. 2413405

2025
[153]

RSC advances, 2024

Setiya, A., et al., MolToxPred: small molecule toxicity prediction using machine learning approach. RSC advances, 2024. 14(6): p. 4201-4220

2024
[154]

Frontiers in Environmental Science, 2016

Mayr, A., et al., DeepTox: toxicity prediction using deep learning. Frontiers in Environmental Science, 2016. 3: p. 80

2016
[155]

arXiv preprint, 2024

Xu, B., et al., Smiles -mamba: Chemical mamba foundation models for drug admet prediction. arXiv preprint, 2024

2024
[156]

de Sá, and D.B

Myung, Y ., A.G. de Sá, and D.B. Ascher, Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic acids research, 2024. 52(W1): p. W469-W475

2024
[157]

IEEE Access, 2024

Alizadehsani, R., et al., Explainable artificial intelligence for drug discovery and development-a comprehensive survey. IEEE Access, 2024

2024
[158]

and V .S

Smaldone, A.M. and V .S. Batista, Quantum -to-classical neural network transfer learning applied to drug toxicity prediction. Journal of Chemical Theory and Computation, 2024. 20(11): p. 4901-4908

2024
[159]

Digital Discovery, 2025

Masarone, S., et al., Advancing predictive toxicology: overcoming hurdles and shaping the future. Digital Discovery, 2025. 4(2): p. 303-315

2025
[160]

Agarwal, P. and D.B. Searls, Literature mining in support of drug discovery. Briefings in Bioinformatics, 2008. 9(6): p. 479-492

2008
[161]

Digital Discovery, 2024

Kosonocky, C.W., Mining patents with large language models elucidates the chemical function landscape. Digital Discovery, 2024. 3(6): p. 1150-1159

2024
[162]

Kant, S. and S. Roy, Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences, 2025

2025
[163]

Drugs and Clinic, 2025

Nikniaz, Z., Large language models in drug discovery: Revolutionizing disease mechanism understanding and clinical trials. Drugs and Clinic, 2025

2025
[164]

Clinical 46 Research in Cardiology, 2017

Cowie, M.R., Electronic health records to facilitate clinical research. Clinical 46 Research in Cardiology, 2017. 106(1): p. 1-9

2017
[165]

Jain, and K

Yadav, S., P. Jain, and K. Vinchurkar, Artificial intelligence in community and hospital pharmacy, in Recent Advances in Biomedical and Pharmaceutical Technologies. 2024

2024
[166]

Bagul, and R.S

Mutha, R.E., V .S. Bagul, and R.S. Tade, An overview of artificial intelligence (AI) in drug delivery and development, in Recent Advances in Biomedical and Pharmaceutical Technologies. 2024

2024
[167]

Tulshan, and T.L

Johnson, T., N. Tulshan, and T.L. Mathuram, Kinase drug discovery: An artificial intelligence revolution. AI in Precision Oncology, 2025

2025
[168]

Discover Artificial Intelligence, 2023

Elahi, M., A comprehensive literature review of the applications of AI techniques through the lifecycle of industrial equipment. Discover Artificial Intelligence, 2023. 3(1): p. 43

2023
[169]

Frontiers in Public Health, 2020

Lan, L., Generative adversarial networks and its applications in biomedical informatics. Frontiers in Public Health, 2020. 8: p. 164

2020
[170]

Holley, K. and M. Mathur, LLMs and Generative AI for Healthcare: The Next Frontier. 2024: CRC Press

2024
[171]

Nature Communications, 2024

Tayebi Arasteh, S., et al., Large language models streamline automated machine learning for clinical studies. Nature Communications, 2024. 15(1): p. 1603

2024
[172]

Bioinformatics Advances, 2023

Zhang, S., Applications of transformer-based language models in bioinformatics: a survey. Bioinformatics Advances, 2023. 3(1): p. 001

2023
[173]

Nucleic Acids Research, 2021

UniProt, C., UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Research, 2021. 49(D1): p. D480-D489

2021
[174]

Science, 2023

Lin, Z., et al., Evolutionary-scale prediction of atomic-level protein structure with a language model. Science, 2023. 379(6637): p. 1123-1130

2023
[175]

Schmidt, and B

Ferruz, N., S. Schmidt, and B. Höcker, ProtGPT2 is a deep unsupervised language model for protein design. Nature communications, 2022. 13(1): p. 4348

2022
[176]

BioRxiv, 2022

Wu, R., High -resolution de novo structure prediction from primary sequence. BioRxiv, 2022

2022
[177]

Critical Reviews in Food Science and Nutrition, 2022

Wang, J., et al., The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. Critical Reviews in Food Science and Nutrition, 2022. 62(14): p. 3979-3989

2022
[178]

Arakawa, and I

Wen, S.J., H. Arakawa, and I. Tamai, Uric acid in health and disease: From physiological functions to pathogenic mechanisms. Pharmacology & Therapeutics,
[179]

47 International Journal of Molecular Sciences, 2021

Yanai, H., et al., Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. 47 International Journal of Molecular Sciences, 2021. 22(1...

2021
[180]

Signal Transduction and Targeted Therapy, 2024

Du, L., et al., Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 2024. 9(1): p. 29

2024
[181]

Jama -Journal of the American Medical Association, 2024

McCormick, N., et al., Serum Urate and Recurrent Gout. Jama -Journal of the American Medical Association, 2024. 331(5): p. 417-424

2024
[182]

Kidney International Reports, 2023

Johnson, R.J., et al., Uric Acid and Chronic Kidney Disease: Still More to Do. Kidney International Reports, 2023. 8(2): p. 229-239

2023
[183]

Redox Biology, 2022

Crawley, W.T., et al., U-shaped association of uric acid to overall -cause mortality and its impact on clinical management of hyperuricemia. Redox Biology, 2022. 51: p. 17

2022
[184]

Seminars in Arthritis and Rheumatism,

Liu, K., et al., Modifiable risk factors and incidence of gout: Estimation of population attributable fraction in the US. Seminars in Arthritis and Rheumatism,
[185]

Journal of Translational Internal Medicine, 2022

Song, J., et al., Prevalence and risk factors of hyperuricemia and gout: a cross - sectional survey from 31 provinces in mainland China. Journal of Translational Internal Medicine, 2022. 10(2): p. 17

2022
[186]

Frontiers in Endocrinology, 2023

Liang, H.L., et al., Incidence density of hyperuricemia and association between metabolism-related predisposing risk factors and serum urate in Chinese adults: a cohort study. Frontiers in Endocrinology, 2023. 14: p. 6

2023
[187]

Lee, S. and D. Shin, A combination of red and processed meat intake and polygenic risk score influences the incidence of hyperuricemia in middle -aged Korean adults. Nutrition Research and Practice, 2024. 18(5): p. 721-745

2024
[188]

Archives of Medical Science, 2024

Jin, Z.K., et al., Global burden and epidemic trends of gout attributable to high body mass index from 1990 to 2019. Archives of Medical Science, 2024. 20(1): p. 71-80

1990
[189]

Jacobsson, and E

Dehlin, M., L. Jacobsson, and E. Roddy, Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology, 2020. 16(7): p. 380-390

2020
[190]

Singh, J.A. and A. Gaffo, Gout epidemiology and comorbidities. Seminars in Arthritis and Rheumatism, 2020. 50: p. S11-S16

2020
[191]

Arthritis & Rheumatology, 2020

Safiri, S., et al., Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990 -2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Arthritis & Rheumatology, 2020. 72(11): p. 1916-1927

1990
[192]

Jmir Public Health and Surveillance, 2023

He, Q.Y ., et al., Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age -Period-Cohort Analysis With Future Burden Prediction. Jmir Public Health and Surveillance, 2023. 9: p. 19

1990
[193]

Therapeutic Advances in Endocrinology and Metabolism, 2024

Han, T.F., et al., Epidemiology of gout - Global burden of disease research from 1990 48 to 2019 and future trend predictions. Therapeutic Advances in Endocrinology and Metabolism, 2024. 15: p. 20

1990
[194]

Cross, M., et al., Global, regional, and national burden of gout, 1990 -2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study

1990
[195]

Jama Internal Medicine, 2022

Yokose, C., et al., Adherence to 2020 to 2025 Dietary Guidelines for Americans and the Risk of New-Onset Female Gout. Jama Internal Medicine, 2022. 182(3): p. 254- 264

2020
[196]

Annals of the Rheumatic Diseases,

Richette, P., et al., 2018 updated European League Against Rheumatism evidence - based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases,

2018
[197]

Arthritis & Rheumatology, 2020

FitzGerald, J.D., et al., 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology, 2020. 72(6): p. 879-895

2020
[198]

Pillinger, and M

Cohen, R.E., M.H. Pillinger, and M. Toprover, Something Old, Something New: the ACR Gout Treatment Guideline and Its Evolution from 2012 to 2020. Current Rheumatology Reports, 2021. 23(1): p. 9

2012
[199]

Standfest, and A

Bartsch, V ., K. Standfest, and A. Hueber, Gout: From the diagnosis to guideline - based treatment. Zeitschrift Fur Gerontologie Und Geriatrie, 2025. 58(2): p. 137 - 146

2025
[200]

Lancet Regional Health-Europe, 2022

Russell, M.D., et al., Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time -series analysis in the United Kingdom. Lancet Regional Health-Europe, 2022. 18: p. 11

2016
[201]

International Journal of Rheumatic Diseases, 2022

Lorenzo, J.P.P., et al., 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. International Journal of Rheumatic Diseases, 2022. 25(1): p. 7-20

2021
[202]

Bmc Rheumatology, 2023

Conley, B., et al., What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines. Bmc Rheumatology, 2023. 7(1): p. 10

2023
[203]

26(1): p

Chan, K.M., et al., Management of gout in primary care of Hong Kong in accordance with international guidelines: any gaps to bridge? Bmc Primary Care, 2025. 26(1): p. 8

2025
[204]

Stamp, L.K. and N. Dalbeth, Moving urate -lowering therapy in gout beyond guideline recommendations. Seminars in Arthritis and Rheumatism, 2024. 65: p. 6

2024
[205]

Lancet, 2020

Mackenzie, I.S., et al., Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 2020. 396(10264): p. 1745-1757

2020
[206]

Chen, and Y .M

Wu, F., L.Y . Chen, and Y .M. Du, Comparison of the efficacy and safety of 49 benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis. Clinical Rheumatology, 2024. 43(5): p. 1745-1754

2024
[207]

Rmd Open, 2024

Bausson, J., et al., Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease. Rmd Open, 2024. 10(1): p. 9

2024
[208]

Drug Design Development and Therapy,

Yanai, K., et al., The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis. Drug Design Development and Therapy,
[209]

Annals of the Rheumatic Diseases, 2023

Roddy, E., et al., Safety of colchicine and NSAID prophylaxis when initiating urate- lowering therapy for gout: propensity score -matched cohort studies in the UK Clinical Practice Research Datalink. Annals of the Rheumatic Diseases, 2023. 82(12): p. 1618-1625

2023
[210]

Clinical Transplantation,

Abdellatif, A., et al., Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV , open-label PROTECT clinical trial. Clinical Transplantation,
[211]

Lancet, 2021

Dalbeth, N., et al., Gout. Lancet, 2021. 397(10287): p. 1843-1855

2021
[212]

Briefings in Bioinformatics, 2024

Zhang, P., et al., Network pharmacology: towards the artificial intelligence -based precision traditional Chinese medicine. Briefings in Bioinformatics, 2024. 25(1): p. 12

2024
[213]

Fitoterapia, 2024

Zhou, Q.X., et al., Integrating multi -level interactive network and in vivo/vitro studies to explore the protective mechanism of Ampelopsis grossedentata in hyperuricemia. Fitoterapia, 2024. 172: p. 15

2024
[214]

& Thomson in alleviating potassium oxonate -induced asymptomatic hyperuricemia in rats

Zhu, Y .L., et al., Integrative metabolomic and network pharmacological analysis reveals potential mechanisms of Cardamine circaeoides Hook.f. & Thomson in alleviating potassium oxonate -induced asymptomatic hyperuricemia in rats. Frontiers in Pharmacology, 2023. 14: p. 14

2023
[215]

Frontiers in Pharmacology, 2022

Xu, L.Q., et al., Integrating network pharmacology and experimental validation to clarify the anti-hyperuricemia mechanism of cortex phellodendri in mice. Frontiers in Pharmacology, 2022. 13: p. 19

2022
[216]

Biomedical Chromatography, 2023

Yu, D.H., et al., Integrative metabolomics and network pharmacology to study the preventative impact of dioscin treatment on hyperuricemia. Biomedical Chromatography, 2023. 37(3): p. 13

2023
[217]

Frontiers in Endocrinology, 2024

Wu, C.H., et al., Identification of inhibitors from a functional food -based plant Perillae Folium against hyperuricemia via metabolomics profiling, network pharmacology and all -atom molecular dynamics simulations. Frontiers in Endocrinology, 2024. 15: p. 22

2024
[218]

Nutrients, 2025

Zhang, S.G., et al., The Potential Mechanism of Alpiniae oxyphyllae Fructus Against 50 Hyperuricemia: An Integration of Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and In Vitro Experiments. Nutrients, 2025. 17(1): p. 17

2025
[219]

Oxidative Medicine and Cellular Longevity, 2021

Liu, L.J., et al., Inflammatory Response and Oxidative Stress as Mechanism of Reducing Hyperuricemia of Gardenia jasminoides -Poria cocos with Network Pharmacology. Oxidative Medicine and Cellular Longevity, 2021. 2021: p. 18

2021
[220]

Food Research International, 2025

Yang, S.X., et al., Molecular mechanisms of Lycii Fructus (Goji berries) against xanthine dehydrogenase in hyperuricemia management: Integrating computational, metabolomic, and experimental approaches. Food Research International, 2025. 204: p. 18

2025
[221]

Journal of Ethnopharmacology, 2024

Ye, J.M., et al., Elucidating the substance basis and pharmacological mechanism of Fufang Qiling granules in modulating xanthine oxidase for intervention in hyperuricemia. Journal of Ethnopharmacology, 2024. 333: p. 14

2024
[222]

Chinese Medicine, 2023

Wang, X.J., et al., Gegen Qinlian Decoction treatment of asymptomatic hyperuricemia by targeting circadian immune function. Chinese Medicine, 2023. 18(1): p. 16

2023
[223]

Molecules, 2024

Wang, X.H., et al., Analysis of Polyphenol Extract from Hazel Leaf and Ameliorative Efficacy and Mechanism against Hyperuricemia Zebrafish Model via Network Pharmacology and Molecular Docking. Molecules, 2024. 29(2): p. 15

2024
[224]

Computational Biology and Chemistry, 2024

Yang, Z.G., et al., Screening of the effective sites of Cichorium glandulosum against hyperuricemia combined with hyperlipidemia and its network pharmacology analysis. Computational Biology and Chemistry, 2024. 110: p. 12

2024
[225]

Evidence -Based Complementary and Alternative Medicine, 2021

Tang, R., et al., Network Pharmacology -Based Investigation of the Mechanism of Action of Plantaginis Herba in Hyperuricemia Treatment. Evidence -Based Complementary and Alternative Medicine, 2021. 2021: p. 8

2021
[226]

Nutrients, 2024

Zhang, Y .M., et al., Network Pharmacology Combined with Experimental Validation to Investigate the Mechanism of the Anti -Hyperuricemia Action of Portulaca oleracea Extract. Nutrients, 2024. 16(20): p. 21

2024
[227]

Computers in Biology and Medicine, 2023

Luo, J.J., et al., Mechanism of anti-hyperuricemia of isobavachin based on network pharmacology and molecular docking. Computers in Biology and Medicine, 2023. 155: p. 10

2023
[228]

Journal of Food Biochemistry, 2025

Yan, S., et al., The Material Basis for the Beneficial Effects of Paidu Powder on Hyperuricemia: A Network Pharmacology and Clinical Study. Journal of Food Biochemistry, 2025. 2025(1): p. 13

2025
[229]

Frontiers in 51 Endocrinology, 2024

Chen, M.L., et al., Potential candidates from a functional food Zanthoxyli Pericarpium (Sichuan pepper) for the management of hyperuricemia: high -through virtual screening, network pharmacology and dynamics simulations. Frontiers in 51 Endocrinology, 2024. 15: p. 21

2024
[230]

Journal of Ethnopharmacology, 2025

Wang, Y .R., et al., Integrating metabolomics with network pharmacology to reveal the mechanism of Poria cocos in hyperuricemia treatment. Journal of Ethnopharmacology, 2025. 337: p. 15

2025
[231]

Frontiers in Nutrition, 2024

Chen, C.Y ., et al., In vitro colonic fermentation of fermented Radix Astragali by Poria cocos and anti-hyperuricemia mechanism based on network pharmacology and experiment verification. Frontiers in Nutrition, 2024. 11: p. 17

2024
[232]

Drug Design Development and Therapy, 2023

Liu, H.B., et al., Dispelling Dampness, Relieving Turbidity and Dredging Collaterals Decoction, Attenuates Potassium Oxonate -Induced Hyperuricemia in Rat Models. Drug Design Development and Therapy, 2023. 17: p. 2287-2301

2023
[233]

Frontiers in Pharmacology, 2022

Zhang, H., et al., Improved effect of fresh ginseng paste (radix ginseng -ziziphus jujube) on hyperuricemia based on network pharmacology and molecular docking. Frontiers in Pharmacology, 2022. 13: p. 12

2022
[234]

South African Journal of Botany, 2025

Chen, N., et al., Molecular mechanisms of saffron petals in the treatment of hyperuricemia: a network pharmacology and experimental verifcation study. South African Journal of Botany, 2025. 180: p. 653-667

2025
[235]

Heliyon, 2024

Wu, Z.Y ., et al., Network pharmacology, molecular docking, combined with experimental verification to explore the role and mechanism of shizhifang decoction in the treatment of hyperuricemia. Heliyon, 2024. 10(3): p. 23

2024
[236]

Traditional Medicine Research, 2025

Zeng, Y .C., et al., Deciphering the molecular mechanisms of Simiaowan in the treatment of hyperuricemia: in vivo and in silico approaches. Traditional Medicine Research, 2025. 10(2): p. 18

2025
[237]

Tropical Journal of Pharmaceutical Research, 2024

Pu, Y ., et al., Investigating the underlying mechanisms of Wuling powder in the management of hyperuricemia based on network pharmacology and molecular docking. Tropical Journal of Pharmaceutical Research, 2024. 23(3): p. 517-527

2024
[238]

Drug Design Development and Therapy, 2023

Huang, J., et al., Wuling San Based on Network Pharmacology and in vivo Evidence Against Hyperuricemia via Improving Oxidative Stress and Inhibiting Inflammation. Drug Design Development and Therapy, 2023. 17: p. 675-690

2023
[239]

Journal of Inflammation Research,

Liu, C.L., et al., Effects of Baicalin on Gout Based on Network Pharmacology, Molecular Docking, and in vitro Experiments. Journal of Inflammation Research,
[240]

Journal of Ethnopharmacology, 2025

Li, G., et al., Mechanism of Biqi capsules in the treatment of gout based on network pharmacology and experimental verification. Journal of Ethnopharmacology, 2025. 337: p. 13

2025
[241]

Journal of Poultry Science, 2025

Li, G.Y ., et al., Network Pharmacology Suggests Mechanisms for Therapeutic Effects of Caulis Sinomenii on Avian Gout. Journal of Poultry Science, 2025. 62: p. 13. 52

2025
[242]

Journal of Biomolecular Structure & Dynamics, 2024

Hang, N.T., et al., Investigation of the mechanism of action of chemical constituents of celery seed against gout disease using network pharmacology, molecular docking, and molecular dynamics simulations. Journal of Biomolecular Structure & Dynamics, 2024. 42(6): p. 2834-2845

2024
[243]

Luo, and B

Liu, Y ., D. Luo, and B. Xu, The combination of molecular docking and network pharmacology reveals the molecular mechanism of Danggui Niantong decoction in treating gout. Medicine, 2022. 101(47): p. 17

2022
[244]

Combinatorial Chemistry & High Throughput Screening, 2025

Liu, W.B., et al., Integrated Network Pharmacology and In -silico Approaches to Decipher the Pharmacological Mechanism of Dioscorea septemloba Thunb in Treating Gout and Its Complications. Combinatorial Chemistry & High Throughput Screening, 2025. 28(1): p. 74-88

2025
[245]

Medicine, 2022

Geng, Y .H., et al., Potential molecular mechanisms of Ermiao san in the treatment of hyperuricemia and gout based on network pharmacology with molecular docking. Medicine, 2022. 101(37): p. 8

2022
[246]

Adnan, and D.H

Oh, K.K., M. Adnan, and D.H. Cho, Network Pharmacology Study on Morus alba L. Leaves: Pivotal Functions of Bioactives on RAS Signaling Pathway and Its Associated Target Proteins against Gout. International Journal of Molecular Sciences, 2021. 22(17): p. 27

2021
[247]

ameliorates gout through the MAPK/PI3K -AKT pathway

Wu, C., et al., Piper longum L. ameliorates gout through the MAPK/PI3K -AKT pathway. Journal of Ethnopharmacology, 2024. 330: p. 12

2024
[248]

Arabian Journal of Chemistry, 2021

Li, T.N., et al., Characterization of the bioactive compounds with efficacy against gout in Guizhi Shaoyao Zhimu Decoction by UHPLC-Q-Orbitrap HRMS combined with network pharmacological analysis. Arabian Journal of Chemistry, 2021. 14(6): p. 19

2021
[249]

Combinatorial Chemistry & High Throughput Screening, 2025: p

Kong, Q.X., et al., Investigation of the Mechanism of Pachyman against Gout Arthritis with Network Pharmacology Analysis and Verification In Vivo. Combinatorial Chemistry & High Throughput Screening, 2025: p. 8

2025
[250]

In Gout Treatment Through Network Pharmacology And Molecular Docking

Tuan, H.Q., et al., Potential Molecular Mechanisms of Paederia Foetida L. In Gout Treatment Through Network Pharmacology And Molecular Docking. Eurobiotech Journal, 2025. 9(2): p. 138-153

2025
[251]

Phytochemical Analysis, 2024

Liu, Q., et al., Rapid screening, isolation, and activity evaluation of potential xanthine oxidase inhibitors in Polyporus umbellatus and mechanism of action in the treatment of gout. Phytochemical Analysis, 2024. 35(1): p. 116-134

2024
[252]

Journal of Separation Science, 2024

Zhuang, S.Y ., et al., Screening, isolation, and activity evaluation of potential xanthine oxidase inhibitors in Poria Cum Radix Pini and mechanism of action in the treatment of gout disease. Journal of Separation Science, 2024. 47(1): p. 16

2024
[253]

Heliyon,

Xiang, G.L., et al., Revealing the potential bioactive components and mechanism of 53 Qianhua Gout Capsules in the treatment of gouty arthritis through network pharmacology, molecular docking and pharmacodynamic study strategies. Heliyon,
[254]

International Immunopharmacology, 2022

Feng, W., et al., Study on the effect and mechanism of quercetin in treating gout arthritis. International Immunopharmacology, 2022. 111: p. 10

2022
[255]

Journal of Ethnopharmacology, 2023

Song, S.Y ., et al., Integrated network pharmacology and gut microbiome analysis to reveal the mechanism of Qu -Zhuo-Tong-Bi decoction against hyperuricemia and gout. Journal of Ethnopharmacology, 2023. 316: p. 16

2023
[256]

Pharmaceutical Biology, 2023

Yang, X.X., et al., Network pharmacology identification and in vivo validation of key pharmacological pathways of Qin Jiao for gout and arthritis. Pharmaceutical Biology, 2023. 61(1): p. 1525-1535

2023
[257]

Journal of Herbal Medicine, 2023

Luo, J.L., et al., Investigation of the mechanism of action of simiao pill against gout using network pharmacology and experimental validation. Journal of Herbal Medicine, 2023. 41: p. 11

2023
[258]

Bmc Complementary Medicine and Therapies, 2022

Xu, H.C., et al., Network pharmacology and in vivo experiments reveal the pharmacological effects and molecular mechanisms of Simiao Powder in prevention and treatment for gout. Bmc Complementary Medicine and Therapies, 2022. 22(1): p. 17

2022
[259]

Frontiers in Pharmacology, 2021

Yang, W.N., et al., Integrated Strategy From In Vitro, In Situ, In Vivo to In Silico for Predicting Active Constituents and Exploring Molecular Mechanisms of Tongfengding Capsule for Treating Gout by Inhibiting Inflammatory Responses. Frontiers in Pharmacology, 2021. 12: p. 17

2021
[260]

Medicine, 2022

Peng, X., et al., The mechanism study of Miao medicine Tongfengting decoction in the treatment of gout based on network pharmacology and molecular docking. Medicine, 2022. 101(51): p. 10

2022
[261]

Journal of Ethnopharmacology, 2023

Bai, L.J., et al., Potential anti -gout properties of Wuwei Shexiang pills based on network pharmacology and pharmacological verification. Journal of Ethnopharmacology, 2023. 305: p. 11

2023
[262]

Frontiers in Pharmacology,

Lin, N., et al., Chinese classical decoction Wuwei Xiaodu Drink alleviates gout arthritis by suppressing NLRP3-Mediated inflammation. Frontiers in Pharmacology,
[263]

Drug Design Development and Therapy, 2024

Fan, Q.Q., et al., Study on the Underlying Mechanism of Yinhua Gout Granules in the Treatment of Gouty Arthritis by Integrating Transcriptomics and Network Pharmacology. Drug Design Development and Therapy, 2024. 18: p. 3089-3112

2024
[264]

Computational Biology and Chemistry,

Li, W.H., et al., Exploration of the mechanism of Zisheng Shenqi decoction against gout arthritis using network pharmacology. Computational Biology and Chemistry,
[265]

Toxicology and Applied Pharmacology, 2021

Xiang, H.L., et al., Network pharmacology and molecular docking analysis on molecular targets: Mechanisms of baicalin and baicalein against hyperuricemic nephropathy. Toxicology and Applied Pharmacology, 2021. 424: p. 12

2021
[266]

Drug Design Development and Therapy, 2021

Li, Q.P., et al., Effect of Berberine on Hyperuricemia and Kidney Injury: A Network Pharmacology Analysis and Experimental Validation in a Mouse Model. Drug Design Development and Therapy, 2021. 15: p. 3241-3254

2021
[267]

Heliyon, 2023

Meng, J., et al., Ameliorative effect of cheqianzi decoction on hyperuricemia and kidney injury and underlying mechanism in rats. Heliyon, 2023. 9(4): p. 13

2023
[268]

Food Bioscience, 2023

Wang, X., et al., Cinnamon essential oil based on NLRP3 inflammasome and renal uric acid transporters for hyperuricemia. Food Bioscience, 2023. 56: p. 17

2023
[269]

Food Bioscience, 2025

Li, C., et al., Integrative analyzing the molecular basis of Clerodendranthus spicatus aqueous extract in hyperuricemia nephropathy via network pharmacology and experimental validation. Food Bioscience, 2025. 66: p. 14

2025
[270]

Journal of Ethnopharmacology, 2024

Liu, H., et al., The Terminalia chebula Retz extract treats hyperuricemic nephropathy by inhibiting TLR4/MyD88/NF-κB axis. Journal of Ethnopharmacology, 2024. 322: p. 14

2024
[271]

Scientific Reports, 2024

Liang, S.Y ., et al., Phyllanthi Fructus ameliorates hyperuricemia and kidney injure via inhibiting uric acid synthesis, modulating urate transporters, and alleviating inflammation. Scientific Reports, 2024. 14(1): p. 19

2024
[272]

Journal of Ethnopharmacology, 2024

Lu, M.X., et al., Fuling -Zexie formula attenuates hyperuricemia -induced nephropathy and inhibits JAK2/STAT3 signaling and NLRP3 inflammasome activation in mice. Journal of Ethnopharmacology, 2024. 319: p. 14

2024
[273]

Molecular Nutrition & Food Research, 2025: p

Qumu, D., et al., Study on the Mechanism of Galangin on Hyperuricemic Nephropathy Based on Metabolomics and Network Pharmacology. Molecular Nutrition & Food Research, 2025: p. 19

2025
[274]

Biomedical Chromatography,

Liang, J.M., et al., Exploring the Material Basis of Taxillus chinensis in the Treatment of Hyperuricemia Nephropathy Through Absorbed Into Blood Component Analysis and Network Pharmacology. Biomedical Chromatography,
[275]

Food & Function, 2025

Kong, X.R., et al., Isorhamnetin ameliorates hyperuricemia by regulating uric acid metabolism and alleviates renal inflammation through the PI3K/AKT/NF -κB signaling pathway. Food & Function, 2025. 16(7): p. 2840-2856

2025
[276]

Bioorganic Chemistry, 2025

Zhou, J.B., et al., Jiangniaosuan formula inhibits hyperuricemia -induced apoptosis of renal tubular epithelial cells via ROS/HIF -1α/EZH2 pathway: A network pharmacology analysis and experimental validation. Bioorganic Chemistry, 2025. 159: p. 21

2025
[277]

Formula in the Improvement of Hyperuricemic Nephropathy in Rats

Amatjan, M., et al., A Novel Approach Based on Gut Microbiota Analysis and 55 Network Pharmacology to Explain the Mechanisms of Action of Cichorium intybus L. Formula in the Improvement of Hyperuricemic Nephropathy in Rats. Drug Design Development and Therapy, 2023. 17: p. 107-128

2023
[278]

Pharmaceutical Biology, 2022

Li, N., et al., Integration of network pharmacology and intestinal flora to investigate the mechanism of action of Chinese herbal Cichorium intybus formula in attenuating adenine and ethambutol hydrochloride-induced hyperuricemic nephropathy in rats. Pharmaceutical Biology, 20...

2022
[279]

Arabian Journal of Chemistry, 2024

Zhou, P.J., et al., Spike lavender essential oil attenuates hyperuricemia and induced renal injury by modulating the TLR4/NF-κB/NLRP3 κ B/NLRP3 signalling pathway. Arabian Journal of Chemistry, 2024. 17(9): p. 22

2024
[280]

Biomedicine & Pharmacotherapy, 2024

Wang, L., et al., Aqueous extract of Phellinus igniarius ameliorates hyperuricemia and renal injury in adenine/potassium oxonate -treated mice. Biomedicine & Pharmacotherapy, 2024. 177: p. 12

2024
[281]

Journal of Ethnopharmacology, 2024

Zeng, L.Y ., et al., Simiao pills alleviates renal injury associated with hyperuricemia: A multi-omics analysis. Journal of Ethnopharmacology, 2024. 333: p. 16

2024
[282]

Wu, and J.D

Yang, F., Z.Y . Wu, and J.D. Gao, Sinapic acid alleviates kidney injury of hyperuricemia mice by inhibiting ERK1/2 -mediated apoptosis of renal tubular epithelial cells. Journal of Functional Foods, 2025. 127: p. 12

2025
[283]

Journal of Food Biochemistry, 2024

Yang, F., et al., Integrating Network Pharmacology and Metabolomics to Explore the Potential Mechanism of β-Sitosterol Against Hyperuricemia Nephropathy. Journal of Food Biochemistry, 2024. 2024: p. 23

2024
[284]

Journal of Medicinal Food, 2024

Li, X.L., et al., Integrating Network Pharmacology and Experimental Validation to Reveal the Mechanism of Vine Grape Tea Polyphenols on Hyperuricemia -Induced Renal Injury in Mice. Journal of Medicinal Food, 2024. 27(4): p. 312-329

2024
[285]

Journal of Ethnopharmacology, 2024

Liu, Y .C., et al., Xanthoceras sorbifolium leaves alleviate hyperuricemic nephropathy by inhibiting the PI3K/AKT signaling pathway to regulate uric acid transport. Journal of Ethnopharmacology, 2024. 327: p. 20

2024
[286]

Scientific Reports, 2015

Doniselli, N., et al., The identification of an integral membrane, cytochrome c urate oxidase completes the catalytic repertoire of a therapeutic enzyme. Scientific Reports, 2015. 5: p. 12

2015
[287]

Nigam, and S.K

Jamshidi, N., K.B. Nigam, and S.K. Nigam, Loss of the Kidney Urate Transporter, Urat1, Leads to Disrupted Redox Homeostasis in Mice. Antioxidants, 2023. 12(3): p. 18

2023
[288]

Discover Oncology, 2025

Li, L.N., et al., Purine metabolism -associated key genes depict the immune landscape in gout patients. Discover Oncology, 2025. 16(1): p. 19

2025
[289]

Food & Function, 2021

Zhou, Q., et al., Various machine learning approaches coupled with molecule simulation in the screening of natural compounds with xanthine oxidase inhibitory 56 activity. Food & Function, 2021. 12(4): p. 1580-1589

2021
[290]

Kaur, and P.M.S

Kumar, N., K. Kaur, and P.M.S. Bedi, Hybridization of molecular docking studies with machine learning based QSAR model for prediction of xanthine oxidase activity. Computational and Theoretical Chemistry, 2023. 1227: p. 9

2023
[291]

Molecular Diversity, 2024

Wu, Y .L., et al., A consensual machine-learning-assisted QSAR model for effective bioactivity prediction of xanthine oxidase inhibitors using molecular fingerprints. Molecular Diversity, 2024. 28(4): p. 2033-2048

2024
[292]

International Journal of Biological Macromolecules,

Yan, X.X., et al., Identification and mechanistic study of piceatannol as a natural xanthine oxidase inhibitor. International Journal of Biological Macromolecules,
[293]

Food Chemistry,

Chen, Q., et al., Virtual-screening of xanthine oxidase inhibitory peptides: Inhibition mechanisms and prediction of activity using machine -learning. Food Chemistry,
[294]

Scientific Reports, 2024

He, Y ., et al., Using deep learning and molecular dynamics simulations to unravel the regulation mechanism of peptides as noncompetitive inhibitor of xanthine oxidase. Scientific Reports, 2024. 14(1): p. 12

2024
[295]

Journal of Chemical Information and Modeling,

Liu, M.H., et al., Mechanistic Study of Protein Interaction with Natto Inhibitory Peptides Targeting Xanthine Oxidase: Insights from Machine Learning and Molecular Dynamics Simulations. Journal of Chemical Information and Modeling,
[296]

Nature Biotechnology, 2021

Zhu, J., et al., Prediction of drug efficacy from transcriptional profiles with deep learning. Nature Biotechnology, 2021. 39(11): p. 1444-+

2021
[297]

European Journal of Radiology, 2025

Xiao, L.S., et al., Developing an interpretable machine learning model for diagnosing gout using clinical and ultrasound features. European Journal of Radiology, 2025. 184: p. 10

2025
[298]

Ieee Transactions on Biomedical Engineering, 2025

Chen, L.Y ., et al., Thinking Like Sonographers: Human-Centered CNN Models for Gout Diagnosis From Musculoskeletal Ultrasound. Ieee Transactions on Biomedical Engineering, 2025. 72(4): p. 1508-1518

2025
[299]

Advanced Science, 2024

Zeng, L., et al., Multimodal Machine Learning -Based Marker Enables Early Detection and Prognosis Prediction for Hyperuricemia. Advanced Science, 2024. 11(34): p. 11

2024
[2021]

Lancet Rheumatology, 2024. 6(8): p. E507-E517

2024
[2024]

5365--5374

64(14): p. 5365--5374

Pith tools

Reviewed August 6, 2026 · model on record in the stance chip above.

[1] [1]

Nature Reviews Drug Discovery, 2023

Mullowney, M.W., et al., Artificial intelligence for natural product drug discovery. Nature Reviews Drug Discovery, 2023. 22(11): p. 895-916

2023

[2] [2]

Molecular Therapy Nucleic Acids, 2023

Chen, W., et al., Artificial intelligence for drug discovery: Resources, methods, and applications. Molecular Therapy Nucleic Acids, 2023. 31: p. 691-702

2023

[3] [3]

Gangwal, A. and A. Lavecchia, Unleashing the power of generative AI in drug discovery. Drug Discovery Today, 2024. 29(6): p. 24

2024

[4] [4]

Briefings in Bioinformatics, 2024

McGibbon, M., et al., From intuition to AI: evolution of small molecule representations in drug discovery. Briefings in Bioinformatics, 2024. 25(1): p. 13

2024

[5] [5]

Pharmaceuticals, 2023

Blanco-González, A., et al., The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals, 2023. 16(6): p. 11

2023

[6] [6]

Expert Opinion on Drug Discovery, 2024

Pinheiro, P.D.M., et al., Molecular hybridization: a powerful tool for multitarget drug discovery. Expert Opinion on Drug Discovery, 2024. 19(4): p. 451-470

2024

[7] [7]

European Journal of Pharmaceutical Sciences, 2023

Vemula, D., et al., CADD, AI and ML in drug discovery: A comprehensive review. European Journal of Pharmaceutical Sciences, 2023. 181: p. 23

2023

[8] [8]

Artificial Intelligence Review, 2023

Askr, H., et al., Deep learning in drug discovery: an integrative review and future challenges. Artificial Intelligence Review, 2023. 56(7): p. 5975-6037

2023